# Bioavailability of Two Sustained-release Theophylline Products in Healthy Males

> **NCT02184247** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 22 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** anhydrous theophylline, 350 mg
- **DRUG:** anhydrous theophylline, 300 mg

## Key facts

- **NCT ID:** NCT02184247
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-04
- **Primary completion:** 1998-05
- **Final completion:** —
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2014-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02184247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02184247, "Bioavailability of Two Sustained-release Theophylline Products in Healthy Males". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02184247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*